Unlock stock picks and a broker-level newsfeed that powers Wall Street.

CStone Pharmaceuticals Leads Our Top 3 Global Penny Stock Picks

In This Article:

As global markets grapple with inflation concerns and trade policy uncertainties, investors are seeking opportunities that can navigate these challenges. Penny stocks, a term that may seem outdated, still represent an intriguing investment area for those interested in smaller or newer companies. These stocks can offer surprising value and potential for significant returns when backed by solid financial foundations.

Top 10 Penny Stocks Globally

Name

Share Price

Market Cap

Financial Health Rating

Yangzijiang Shipbuilding (Holdings) (SGX:BS6)

SGD2.37

SGD9.36B

★★★★★☆

NEXG Berhad (KLSE:DSONIC)

MYR0.265

MYR737.27M

★★★★★★

Cloudpoint Technology Berhad (KLSE:CLOUDPT)

MYR0.81

MYR430.6M

★★★★★★

DXN Holdings Bhd (KLSE:DXN)

MYR0.50

MYR2.49B

★★★★★★

Bosideng International Holdings (SEHK:3998)

HK$4.13

HK$47.68B

★★★★★★

Lever Style (SEHK:1346)

HK$1.29

HK$831.57M

★★★★★★

Next 15 Group (AIM:NFG)

£3.02

£300.36M

★★★★☆☆

Warpaint London (AIM:W7L)

£3.775

£304.97M

★★★★★★

Foresight Group Holdings (LSE:FSG)

£3.74

£425.4M

★★★★★★

Bisalloy Steel Group (ASX:BIS)

A$3.23

A$151.84M

★★★★★★

Click here to see the full list of 5,701 stocks from our Global Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

CStone Pharmaceuticals

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: CStone Pharmaceuticals is a biopharmaceutical company focused on researching, developing, and commercializing immuno-oncology and precision medicines for cancer patients in China and globally, with a market cap of HK$4.72 billion.

Operations: The company generates revenue primarily from its pharmaceuticals segment, amounting to CN¥456.53 million.

Market Cap: HK$4.72B

CStone Pharmaceuticals is advancing its biopharmaceutical pipeline with promising clinical developments, despite being unprofitable. The company recently submitted a Phase Ib trial application for CS5001, an ROR1-targeting ADC, and dosed the first patient in a global Phase I trial for CS2009, a novel trispecific antibody. These initiatives aim to reshape cancer treatment landscapes. CStone's strategic partnerships enhance its market reach, as seen in the recent commercialization agreement with SteinCares for sugemalimab across Latin America. Although debt levels have increased over five years, CStone maintains sufficient cash reserves to support ongoing operations and development efforts.

SEHK:2616 Revenue & Expenses Breakdown as at Mar 2025
SEHK:2616 Revenue & Expenses Breakdown as at Mar 2025

Aotecar New Energy Technology

Simply Wall St Financial Health Rating: ★★★★★☆